Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2016

View Archived Issues

PDS Biotechnology's PDS-0101 shows promise in phase I/IIa study

Vertex advances plans for next-generation correctors for cystic fibrosis

Bayer compares BAY-1003803 formulations in psoriasis plaque test

Theravance Biopharma reports data from phase I MAD study of TD-0714

Lexicon Pharmaceuticals reports positive results for phase II trial of sotagliflozin

Moleculin Biotech announces positive data for WP-1122 toxicity testing in mice

Debiopharm International completes phase II trial of Debio-1450

Sanofi, WRAIR and Fiocruz agree principles of collaboration for Zika vaccine development

Minerva Neurosciences reports data for phase IIb trial of MIN-101

[225Ac]PSMA-617 as promising new PSMA-targeted radiation therapy for mCRPC

Entasis Therapeutics starts phase I trial of ETX-2514

Novel radioligands show promise as imaging and therapeutic agents for GRPR-expressing tumors

ApeX Therapeutics changes corporate name to Apexian Pharmaceuticals

Changzhou Longthera Pharmaceuticals patents CDK/cyclin D1 inhibitors

Hangzhou Innogate Pharma discloses IDO-1 and/or TDO inhibitors

Selecta Biosciences doses first patient in phase II trial of SEL-212

Eli Lilly describes GOAT inhibitors

Merck & Co. develops FXIa and/or plasma kallikrein inhibitors

Allergan completes tender offer for Vitae Pharmaceuticals

Ultragenyx Pharmaceutical starts phase III trial of burosumab

Silvergate announces U.S. availability of Qbrelis

New BRAC2 mutation characterized in a family with male and female breast cancer

Apitope enrolls first patient in phase I trial of ATX-GD-59

Boehringer Ingelheim discloses topline data from phase III trial of BI-695501

Myriad RBM to work with Sanofi to perform biomarker analysis of blood samples from ELIXA trial

Serodus, Lam Therapeutics and Actelion receive FDA orphan designations for treatments in PAH

MYH3 gene variants may cause congenital scoliosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...